Ticker: AMGN

Amgen

Biotech Healthcare Drug Manufacturers - General

Price 383.56

Reco Hold Potential 60 Risk 70 Updated 2026-09-09

Official website

Forecast impact

positive

Target +11.2% target fill 90.0%

Reaction D5 -10.89% · D10 pending market trust

Impact Potential +3 · Risk -1 valid until 2026-10-04

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Amgen is a biotechnology company focused on developing and manufacturing innovative therapies for serious illnesses. Its core products include biologic medicines for cancer, kidney disease, and inflammatory disorders. Major business segments encompass oncology, nephrology, and inflammation, with primary revenue sources derived from sales of its flagship drugs, including Enbrel and Neulasta. The company also invests in research and development to expand its product pipeline.

Investment Profile

The investment profile of Amgen is more aligned with dividends and value investors, given its consistent dividend yield and established market presence. The stock exhibits moderate volatility and has shown resilience in its earnings, making it suitable for those seeking stable returns. Investors may consider a medium to long-term horizon for potential growth, while the liquidity is moderate, reflecting a balanced approach to investment.

Category: Biotech Sector: Healthcare Industry: Drug Manufacturers - General Investment style: Growth Horizon: Medium-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-09-10

EPS (TTM) — earnings per share for the last 12 months, $: 16.22
Revenue QoQ — quarter-over-quarter revenue growth: 16.7%
EPS surprise: 11.9%
20d volatility: 2.6%
Dividend yield: 2.5%
last ex-date: 2026-08-21

AI recommendation changes

Date	Before	After	Reason
2026-09-09	Buy	Hold	Negative momentum and high risk offset solid fundamentals.
2026-08-06	Hold	Buy	Strong momentum and solid EPS surprise support growth potential.
2026-08-04	Buy	Hold	Weak fundamentals and mixed momentum signal caution.
2026-06-23	Sell	Buy	Mixed performance; cautious outlook on revenue decline.
2026-06-19	Buy	Sell	Weak momentum and fundamentals raise uncertainty.
2026-06-15	Hold	Buy	Solid fundamentals but mixed momentum signals.
2026-06-05	Sell	Hold	Mixed performance; monitor for recovery signals.
2026-06-03	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-05-26	Sell	Hold	Weak fundamentals and mixed momentum signal caution.
2026-05-18	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-05-08	—	Hold	Weak fundamentals and negative momentum raise concerns.
2026-05-02	Buy	Hold	Компания Amgen демонстрирует стабильный рост выручки и дивидендную доходность, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе.
2026-01-21	Hold	Buy	Компания Amgen демонстрирует положительную динамику цен на акции за последние 60 и 120 дней, что указывает на устойчивый рост. Несмотря на отсутствие данных по EPS и доходам, текущие тренды и momentum предполагают хороши

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-09-04	Wells Fargo	Target Raised	— → 435	444.12
2026-08-20	Piper Sandler	Target Raised	427 → 457	442.36
2026-08-19	Morgan Stanley	Target Raised	351 → 362	440.28
2026-08-19	Argus Research	Target Raised	375 → 460	439.95
2026-08-18	Cantor Fitzgerald	Target Raised	350 → 400	419.38
2026-08-18	Mizuho Securities	Target Raised	303 → 352	419.38
2026-08-14	Barclays	Target Raised	360 → 380	417.84
2026-08-10	Guggenheim	Target Raised	— → 388	410.945
2026-08-06	Bernstein	Target Raised	335 → 345	407.83
2026-08-05	Scotiabank	Target Raised	385 → 450	406.2515
2026-08-05	Oppenheimer	Target Raised	400 → 450	390.02
2026-08-05	RBC Capital	Target Raised	370 → 400	390.02
2026-08-05	Robert W. Baird	Target Raised	215 → 230	390.02
2026-08-05	Canaccord Genuity	Target Raised	366 → 384	390.02
2026-08-05	BMO Capital	Target Raised	400 → 450	390.02
2026-07-29	Barclays	Target Raised	350 → 360	393.1
2026-07-13	UBS	Target Raised	400 → 420	358.68
2026-07-13	Guggenheim	Target Raised	— → 343	363.39
2026-07-08	Morgan Stanley	Target Lowered	340 → 333	368.1
2026-07-01	BMO Capital	Update	— → 400	362.4476
2026-06-16	Mizuho Securities	Target Raised	— → 303	350.53
2026-06-09	Morgan Stanley	Target Raised	— → 340	344.565
2026-06-05	Goldman Sachs	Target Lowered	425 → 389	352.62
2026-05-14	Piper Sandler	Target Lowered	432 → 427	336.45
2026-05-04	Guggenheim	Target Lowered	351 → 340	329.82
2026-05-01	Morgan Stanley	Target Raised	326 → 332	329.305
2026-04-20	Canaccord Genuity	Update	— → 366	350.16
2026-04-10	Morgan Stanley	Target Raised	309 → 326	352.59
2026-04-09	Guggenheim	Target Raised	347 → 351	355.6
2026-04-08	Truist Financial	Target Raised	319 → 325	349.81
2026-03-10	Jefferies	Update	— → 350	373.07501
2026-03-05	Leerink Partners	Update	— → 355	367.6
2026-02-19	Barclays	Update	— → 185	375.5
2026-02-19	Wells Fargo	Target Raised	325 → 375	379.73
2026-02-18	Piper Sandler	Target Raised	381 → 432	373.36
2026-02-11	Mizuho Securities	Target Raised	280 → 295	364.65

News Page 1 of 1

Jim Cramer Advises Investors to Diversify Beyond AI Stocks, Highlighting Opportunities in Aerospace, Fintech, Healthcare, and Energy

09/08/2026, 03:37 PM economy research finance healthcare Enbridge Affirm Holdings Boeing Robinhood Enterprise Products Partners Medtronic Amgen

Jim Cramer advises investors to diversify their portfolios beyond the heavily concentrated artificial intelligence sector, highlighting several alternative investment opportunities across various industries.

Novartis Faces Setback in Cardiovascular Drug Trial, Impacting Market Outlook for Lp(a) Treatments

09/07/2026, 10:36 PM business review healthcare pharma Ionis Pharmaceuticals Amgen Novartis Eli Lilly

Novartis' recent failure in a key cardiovascular trial for its cholesterol drug pelacarsen has raised concerns about the viability of treatments targeting Lp(a), a cholesterol variant linked to increased heart disease risk, impacting not only Novartis but also its competitors Amgen and Eli Lilly.

Market Movers: Anticipation Builds Ahead of Nvidia’s Earnings Report and Insights on Data Center Stocks

08/24/2026, 04:37 PM investing review Micron General Electric BMO Financial Group Expedia Group Nvidia Dick's Sporting Goods Amgen

Investors should pay attention to upcoming earnings reports from Nvidia and Dick's Sporting Goods, as well as trends in the data center sector, which could influence stock performance significantly.

Analysts Ritholtz Wealth Management highlight Merck & Co., Inc. (MRK) and Amgen (AMGN) as biotech stocks show significant breakout potential

08/24/2026, 08:38 AM investing review Analysts: analysts, Ritholtz biotech Merck Amgen

Merck's recent Phase 3 trial success in combination therapy has significantly boosted its stock, indicating a positive shift in investor sentiment towards its pipeline. This development, along with Amgen's strong performance, highlights a broader resurgence in the biotech sector, which could attract more investor interest.

Drugmakers Compete to Innovate in Obesity Treatment Market with New GLP-1 Pills and Alternative Therapies

06/13/2026, 05:36 AM business review healthcare AstraZeneca Novo Nordisk Amgen Pfizer Eli Lilly

The race among drugmakers to develop innovative obesity treatments is intensifying, with Eli Lilly and Novo Nordisk leading the market while new entrants explore alternative therapies. This competition is crucial as it could reshape the landscape of weight-loss medications and impact pricing and accessibility for patients.

Quantinuum Opens Trading at $68 per Share Following $1.68 Billion IPO

06/04/2026, 11:31 AM economy announcement software JPMorgan Chase Honeywell Amgen

Quantinuum's IPO raised $1.68 billion, pricing shares at $60 each, and opening at $68, reflecting strong investor interest in quantum computing despite the company's recent financial losses.